Pancreatic cancer is often diagnosed at an advanced stage and is characterized by a poor prognosis and rising mortality. Galectin-3 (Gal-3), a chimeric protein, plays a multifaceted role in driving the progression of pancreatic adenocarcinoma (PAAD). While its interaction with tumor microenvironment cells is well-documented, the specific mechanisms by which Gal-3 mediates tumor–stromal interactions and promotes metabolic reprogramming linked to drug resistance remain unclear.

This research, published in the Genes & Diseases journal by a team from Capital Medical University, Peking University Cancer Hospital & Institute, Shandong First Medical University, and Cardiff University School of Medicine elucidates whether the inhibition of Gal-3 expression in tumor or stromal cells can improve the efficacy of gemcitabine, a standard chemotherapeutic agent for PAAD.

Analysis of multiple RNA sequencing public datasets revealed that Gal-3 is not only remarkably up-regulated in tumors but also significantly associated with the tumor-associated fibroblasts (TAFs) in PAAD patients. Notably, high Gal-3 expression correlated strongly with poor patient outcomes in pancreatic cancer. Using a co-culture model of PAAD cells and pancreatic stellate cells, the researchers demonstrated that Gal-3 mediated the Ca²⁺/⁻calcineurin–NFAT pathway to increase the transcription of C–C motif chemokine 2 (CCL2) and basigin (BSG) in TAFs.

Interestingly, the Gal-3–mediated signaling cascade was shown to suppress oxidative phosphorylation in tumor cells. Elevated CCL2, secreted by Gal-3-activated TAFs, inhibited NADPH oxidase 1 (NOX1) activity, reducing ROS levels, mitochondrial ATP production, and oxygen consumption. Additionally, Gal-3 induced the expression of CCL2 and BSG via calcium-dependent calcineurin (CALN) dephosphorylation of nuclear factor of activated T-cells 1 (NFAT1), promoting their transcription in TAFs.

Further investigations revealed that Gal-3 enhances gemcitabine resistance via two mechanisms, CCL2-CCR2 signaling and the BSG-FAK-ERK pathway. Inhibition of these pathways reversed drug resistance and reduced tumor sphere formation. In orthotopic pancreatic xenograft models, co-treatment with modified citrus pectin (MCP)—a natural Gal-3 inhibitor—and AC-73, in combination with gemcitabine, significantly reduced tumor growth without adverse effects. These findings suggest that Gal-3 inhibition in vivo can effectively potentiate the anti-tumor effect of gemcitabine.

In summary, this study demonstrates that by inhibiting Gal-3 in combination with gemcitabine in the tumor microenvironment represents a valuable innovation in the pharmacological treatment of pancreatic cancer. Overall, given its food-derived origin and safety profile, MCP presents a promising avenue for further development as an adjunctive therapy in pancreatic cancer.

Reference

Title of Original Paper: Galectin-3 in tumor-stromal cells enhances gemcitabine resistance in pancreatic adenocarcinoma by suppressing oxidative phosphorylation

Journal: Genes & Diseases

Genes & Diseases is a journal for molecular and translational medicine. The journal primarily focuses on publishing investigations on the molecular bases and experimental therapeutics of human diseases. Publication formats include full length research article, review article, short communication, correspondence, perspectives, commentary, views on news, and research watch.

DOI: https://doi.org/10.1016/j.gendis.2025.101702

Funding Information:

• Noncommunicable Chronic Diseases-National Science and Technology Major Project (China) (No. 2024ZD0520200)
• National Natural Science Foundation of China (No. 81802353)
• Foundation of China Association for Promotion of Health Science and Technology (No. JKHY2024003)
• Science Foundation of Peking University Cancer Hospital (China) (No. A003004)
• Research Enhancement Fund of Shandong Provincial Hospital (China) (No. 2024TS12)

# # # # # #

Genes & Diseases publishes rigorously peer-reviewed and high quality original articles and authoritative reviews that focus on the molecular bases of human diseases. Emphasis is placed on hypothesis-driven, mechanistic studies relevant to pathogenesis and/or experimental therapeutics of human diseases. The journal has worldwide authorship, and a broad scope in basic and translational biomedical research of molecular biology, molecular genetics, and cell biology, including but not limited to cell proliferation and apoptosis, signal transduction, stem cell biology, developmental biology, gene regulation and epigenetics, cancer biology, immunity and infection, neuroscience, disease-specific animal models, gene and cell-based therapies, and regenerative medicine.

Scopus Cite Score: 8.4 | Impact Factor: 9.4

# # # # # #

More information: https://www.keaipublishing.com/en/journals/genes-and-diseases/
Editorial Board: https://www.keaipublishing.com/en/journals/genes-and-diseases/editorial-board/
All issues and articles in press are available online in ScienceDirect (https://www.sciencedirect.com/journal/genes-and-diseases).
Submissions to Genes & Disease may be made using Editorial Manager (https://www.editorialmanager.com/gendis/default.aspx ).
Print ISSN: 2352-4820
eISSN: 2352-3042
CN: 50-1221/R
Contact Us: editor@genesndiseases.com
X (formerly Twitter): @GenesNDiseases (https://x.com/GenesNDiseases)